News – Page 2

Syntrix Presents at the 2014 ACA Summit in Washington, D.C.

Syntrix was invited to present at the 2014 Angel Capital Association (ACA) Summit co-sponsored by the National Heart Lung and Blood Institute (NHLBI).  This conference brings together businesses, angel investors, and strategic partners from the biotech and pharmaceutical industries. It features presentations by top NHLBI-funded companies with innovative technologies.  The Syntrix presentation featured SX-682, the […]

Syntrix Presents at the 2013 NHLBI Innovation Conference in San Francisco

Syntrix was one of six breakthrough technology companies invited to present at the 2013 Innovation Conference sponsored by the National Heart Lung and Blood Institute (NHLBI).  This conference brings together businesses, investors, and strategic partners from the biotech and pharmaceutical industries. It features presentations by top NHLBI-funded companies with innovative technologies.  The Syntrix presentation featured […]

Science Education at Syntrix: 2013 Summer Interns Start!

With the arrival of our new interns at Syntrix, it must be summer again. It’s always inspiring to see new highly motivated students in our laboratories eager to contribute to the Syntrix culture and expand their education by learning directly at the bench in a real world entrepreneurial environment. This year we will be hosting Lindsey Kornowske, who […]

In the News: Syntrix Wins Judgement of $115 Million in Largest Patent Verdict in Washington State History

Syntrix Biosystems wins final judgment of $115 million in patent case against Illumina, Inc.  Decision follows largest patent verdict in Washington state history. Read the full press release.

Syntrix Reports Discovery of Stem-Chelate-Loop Probe Exhibiting Reversible Metal-Dependent Destabilization and Stabilization of Binding to Unmodified DNA

Congratulations to Syntrix scientists on their latest publication, which appeared in the journal Bioconjugate Chemistry. Abstract: Herein, we report the discovery of a novel DNA probe with a stem-chelate-loop structure, wherein the stability of the probe-target duplex can be modulated lower or higher using a narrow concentration range of dilute transition metal ions (0.1-10 μM). Oligonucleotide probes containing two […]

Syntrix Presents at the 2012 Life Science Invest Northwest Conference in Seattle

Syntrix President John A Zebala, MD, PhD presented at the 2012 Life Science Invest Northwest (LSINW) Conference in Seattle. The Syntrix presentation featured Omnitram, the company’s new oral treatment for acute, chronic and neuropathic pain. LSINW brings together nearly 1,000 attendees from public and private companies, research institutions and the global health communit. Read about Omnitram in our pipeline.

Syntrix Receives $1.8M Grant to Develop Omnitram for Acute and Chronic Pain

Congratulations to Syntrix scientists on their new grant for $1.8M from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH). The project title is “Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers.” Here is the public health relevance from the proposal: “Tramadol is a widely prescribed analgesic, but 10% of the U.S. population is resistant […]

Dr. Zebala Invited to Speak at the 2011-2012 David Rogers Health Policy Colloquium at the Weill Cornell Medical College

Dr. John Zebala, President and CEO of Syntrix Biosystems and alumnus of the Weill Cornell Medical College was an invited speaker at the 2011-2012 David E. Rogers Health Policy Colloquium. Dr. Zebala shared his experience with the current business and regulatory challenges facing early-stage drug development. Learn more about the life of David E. Rogers. 

Collaboration: Syntrix Receives $557K Grant to Develop New Drug for Multiple Drug Resistant Tuberculosis

Syntrix scientists will collaborate with Dr. Andrew Bognar of the University of Toronto on a $557K tuberculosis grant from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). The project title is “Transition-State Analogue Inhibitors of Dihydrofolate Synthetase for MDR/XDR TB.” The public health relevance from the proposal: “Multidrug-resistant tuberculosis and extensively drug […]

Syntrix Receives $3.8M Grant to Develop New Treatment for COPD and Lung Disease Affecting Newborns

Congratulations to Syntrix scientists on their new grant for $3.8M from the National Hearth Lung and Blood Institute (NHBLI) of the National Institutes of Health (NIH). The project title is “Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD.” Here is the public health relevance from the proposal: “Pulmonary inflammatory diseases such as bronchopulmonary dysplasia (BPD) […]